Trk kinase inhibitors as new treatments for cancer and pain

Bibliography

• Cohen P. Protein kinases–the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002;1:309-15
   PubMed Web of Science ®Google Scholar
• Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004;4:361-70
   PubMed Web of Science ®Google Scholar
• Patapoutian A, Reichardt LF. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol 2001;11:272-80
   PubMed Web of Science ®Google Scholar
• Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 2001;169:107-14
   PubMed Web of Science ®Google Scholar
• Desmet CJ, Peeper DS. The neurotrophic receptor TrkB: a drug target in anti-cancer therapy? Cell Mol Life Sci 2006;63:755-9
   PubMed Web of Science ®Google Scholar
• Papatsoris AG, Liolitsa D, Deliveliotis C. Manipulation of the nerve growth factor network in prostate cancer. Expert Opin Investig Drugs 2007;16:303-9
   PubMed Web of Science ®Google Scholar
• Weeraratna AT, Arnold JT, George DJ, et al. Rational basis for Trk inhibition therapy for prostate cancer. Prostate 2000;45:40-8
   Google Scholar
• Miknyoczki SJ, Lang D, Huang L, et al. Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: expression patterns and effects on in vitro invasive behavior. Int J Cancer 1999;81:417-27
   PubMedGoogle Scholar
• Sclabas GM, Fujioka S, Schmidt C, et al. Overexpression of tropomyosin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res 2005;11:440-9
   PubMed Web of Science ®Google Scholar
• Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002;2:367-76
   PubMed Web of Science ®Google Scholar
• Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16
   PubMed Web of Science ®Google Scholar
• Izbicka E, Izbicki T. Therapeutic strategies for the treatment of neuroblastoma. Curr Opin Investig Drugs 2005;6:1200-14
   Google Scholar
• Ho R, Eggert A, Hishiki T, et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 2002;62:6462-66
   PubMed Web of Science ®Google Scholar
• Tacconelli A, Farina AR, Cappabianca L, et al. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell 2004;6:347-60
   PubMed Web of Science ®Google Scholar
• Bardelli A, Parsons DW, Silliman N, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003;300:949
   PubMed Web of Science ®Google Scholar
• Davies H, Hunter C, Smith R, et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005;65:7591-5
   PubMed Web of Science ®Google Scholar
• Indo Y, Tsuruta M, Hayashida Y, et al. Mutations in the TrkA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet 1996;13:485-8
   PubMed Web of Science ®Google Scholar
• Indo Y, Mardy S, Miura Y, et al. Congenital insensitivity to pain with anhidrosis (CIPA): Novel mutations of the TrkA (NTRK1) gene, a putative uniparental disomy, and a linkage of the mutant TrkA and PKLR genes in a family with CIPA and pyruvate kinase deficiency. Hum Mutat 2001;18:308-18
   PubMedGoogle Scholar
• Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 2006;29:507-38
   PubMed Web of Science ®Google Scholar
• Hefti FF, Rosenthal A, Walicke PA, et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci 2006;27:85-91
   PubMedGoogle Scholar
• Winston JH, Toma H, Shenoy M, et al. Acute pancreatitis results in referred mechanical hypersensitivity and neuropeptide up-regulation that can be suppressed by the protein kinase inhibitor k252a. J Pain 2003;4:329-37
   PubMed Web of Science ®Google Scholar
• Zahn PK, Subieta A, Park SS, et al. Effect of blockade of nerve growth factor and tumor necrosis factor on pain behaviors after plantar incision. J Pain 2004;5:157-63
   PubMed Web of Science ®Google Scholar
• Read SJ, Dray A. Osteoarthritic pain: a review of current, theoretical and emerging therapeutics. Expert Opin Investig Drugs 2008;17:619-40
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Nardi K, Mancini ML, et al. Nerve growth factor and brain-derived neurotrophic factor: potential targets for migraine treatment? Expert Opin Ther Patents 2008;18:705-21
   Web of Science ®Google Scholar
• Schnitzer TJ, Lane NE, Smith MD, et al. Efficacy and safety of tanezumab (PF04383119), an anti-nerve growth factor (NGF) antibody, for moderate to severe pain due to osteoarthritis (OA) of the knee: A randomized trial [abstract PT214]. 12th World Congress on Pain, August 17-22, 2008, Glasgow, United Kingdom;
   Google Scholar
• Amgen Inc. Heteroaryl-substituted alkyne compounds and methods of use. WO2006044823; 2006
   Google Scholar
• Sullivan JE, Holdgate GA, Campbell D, et al. Prevention of MKK6-dependent activation by binding to p38α MAP kinase. Biochemistry 2005;44:16475-90
   PubMed Web of Science ®Google Scholar
• Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 2002;109:275-82
   PubMed Web of Science ®Google Scholar
• Hubbard SR. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 1997;16:5572-81
   PubMed Web of Science ®Google Scholar
• Cee VJ, Albrecht BK, Geuns-Meyer S, et al. Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase. J Med Chem 2007;50:627-40
   PubMed Web of Science ®Google Scholar
• AstraZeneca AB, AstraZeneca UK Limited. Pyrazole derivatives as inhibitors of receptor tyrosine kinases. WO2005049033; 2005
   Google Scholar
• Wang T, Lamb ML, Scott DA, et al. Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases. J Med Chem 2008;51:4672-84
   PubMed Web of Science ®Google Scholar
• AstraZeneca AB, AstraZeneca UK Limited. Chemical compounds. WO2005103010; 2005
   Google Scholar
• AstraZeneca AB, AstraZeneca UK Limited. Pyrazolylaminopyridine derivatives useful as kinase inhibitors. WO2006082392; 2006
   Google Scholar
• AstraZeneca AB, AstraZeneca UK Limited. Pyrazolyl-amino-substituted pyrimidines and their use in the treatment of cancer. WO2006117560; 2006
   Google Scholar
• AstraZeneca AB, AstraZeneca UK Limited. Chemical compounds. WO2006123113; 2006
   Google Scholar
• AstraZeneca AB, AstraZeneca UK Limited. Chemical compounds. WO2006087530; 2006
   Google Scholar
• AstraZeneca AB, AstraZeneca UK Limited. Chemical compounds. WO2006087538; 2006
   Google Scholar
• Hudkins RL, Josef KA. Pyrazole Trk kinase inhibitors for the treatment of cancer. Expert Opin Ther Patents 2007;17:351-6
   Web of Science ®Google Scholar
• AstraZeneca AB. Use of pyrazolyl-pyrimidine derivatives in the treatment of pain. WO2006115452; 2006
   Google Scholar
• AstraZeneca AB. Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain. WO2008054291; 2008
   Google Scholar
• AstraZeneca AB. Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment of prophylaxis of pain. WO2008054292; 2008
   Google Scholar
• Bayer Pharmaceuticals Corporation. Urea compounds useful in the treatment of cancer. WO2007064872; 2007
   Google Scholar
• Bayer Pharmaceuticals Corporation. Pyrazolyl urea derivatives useful in the treatment of cancer. WO2007059202; 2007
   Google Scholar
• Bayer Pharmaceuticals Corporation. Substituted pyrazolyl urea derivatives useful in the treatment of cancer. WO2005110994; 2005
   Google Scholar
• Regan J, Breitfelder S, Cirillo P, et al. Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate. J Med Chem 2002;45:2994-3008
   PubMed Web of Science ®Google Scholar
• Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61
   PubMed Web of Science ®Google Scholar
• Das J, Furch JA, Liu C, et al. Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors. Bioorg Med Chem Lett 2006;16:3706-12
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company. Thiazolyl inhibitors of Tec family tyrosine kinases. WO200250071; 2002
   Google Scholar
• Kim SH, Tokarski JS, Leavitt KJ, et al. Identification of 2-amino-5-(thioaryl)thiazoles as inhibitors of nerve growth factor receptor TrkA. Bioorg Med Chem Lett 2008;18:634-9
   Google Scholar
• Bristol-Myers Squibb Company. Pyrrolotriazine kinase inhibitors. WO2007061882; 2007
   Google Scholar
• Pfizer Products Inc. Pyrrolopyrimidine derivatives. WO2004056830; 2004
   Google Scholar
• Hunt JT, Mitt T, Borzilleri R, et al. Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor template. J Med Chem 2004;47:4054-9
   PubMed Web of Science ®Google Scholar
• Ghose AK, Herbertz T, Pippin DA, et al. Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. J Med Chem 2008;51:5149-71
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company. Pyrrolotriazine kinase inhibitors. WO2008057994; 2008
   Google Scholar
• Ruggeri B, Miknyoczki S, Singh J, et al. Role of neurotrophin–Trk interactions in oncology: the anti-tumor efficacy of potent and selective Trk tyrosine kinase inhibitors in pre-clinical tumor models. Curr Med Chem 1999;6:845-57
   PubMed Web of Science ®Google Scholar
• Hexner EO, Serdikoff C, Jan M, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008;111:5663-71
   PubMed Web of Science ®Google Scholar
• Cephalon Inc. Novel fused pyrrolocarbazoles. US20050137245; 2005
   Google Scholar
• Cephalon Inc. Novel fused pyrrolocarbazoles. US20050143442; 2005
   Google Scholar
• Cephalon Inc. Isomeric fused pyrrolocarbozoles and isoindolones. US20050107458; 2005
   Google Scholar
• Cephalon Inc. Selected fused pyrrolocarbozoles. WO200217914; 2002
   Google Scholar
• Gingrich DE, Yang SX, Gessner GW, et al. Synthesis, modeling, and in vitro activity of (3'S)-epi-K-252a analogues. Elucidating the stereochemical requirements of the 3'-sugar alcohol on TrkA tyrosine kinase activity. J Med Chem 2005;48:3776-83
   Google Scholar
• Tripathy R, Angeles TS, Yang SX, et al. TrkA kinase inhibitors from a library of modified and isosteric staurosporine aglycone. Bioorg Med Chem Lett 2008;18:3551-5
   Google Scholar
• Faivre S, Demetri G, Sargent W, et al. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007;6:734-45
   PubMed Web of Science ®Google Scholar
• SmithKline Beecham Corporation. Chemical compounds. WO200327111; 2003
   Google Scholar
• Glaxo Group Limited. Substituted oxindole derivatives as tyrosine kinase inhibitors. WO200220479; 2002
   Google Scholar
• Glaxo Group Limited. Oxindole derivatives. WO200220513; 2002
   Google Scholar
• Wood ER, Kuyper L, Petrov KG, et al. Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg Med Chem Lett 2004;14:953-7
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Substituted oxindole derivatives as tyrosine kinase inhibitors. US20050228025; 2005
   Google Scholar
• Japan Tobacco Inc. Neurotrophin-inhibiting condensed pyrazoles and analgesics containing them. JP2003231687; 2003
   Google Scholar
• Johnson & Johnson. Alkylquinoline and alkylquinazoline kinase modulators. US2006281772; 2006
   Google Scholar
• Johnson & Johnson. Aminoquinoline and aminoquinazoline kinase modulators. WO2006135649; 2006
   Google Scholar
• Johnson & Johnson. Aminopyrimidines as kinase modulators. US2006281764; 2006
   Google Scholar
• Johnson & Johnson. Aminopyrimidines as kinase modulators. US2007021435; 2007
   Google Scholar
• Pharmacia Italia SPA. Pyrrolo[3,4-c] pyrazolederivatives active as kinase inhibitors. WO200505427; 2005
   Google Scholar
• Fancelli D, Moll J, Varasi M, et al. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: Identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem 2006;49:7247-51
   PubMed Web of Science ®Google Scholar
• Carpinelli P, Ceruti R, Giorgini ML, et al. Pha-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007;6:3158-68
   PubMed Web of Science ®Google Scholar
• Novartis AG. Heterocyclic compounds as antiinflammatory agents. WO200852734; 2008
   Google Scholar
• IRM LLC. Compounds and compositions as kinase inhibitors. WO2008073480; 2008
   Google Scholar
• Pfizer Products Inc. Isothiazole derivatives useful as anticancer agents. WO2004011461; 2004
   Google Scholar
• Lippa B, Morris J, Corbett M, et al. Discovery of novel isothiazole inhibitors of the TrkA kinase: structure–activity relationship, computer modeling, optimization, and identification of highly potent antagonists. Bioorg Med Chem Lett 2006;16:3444-8
   PubMed Web of Science ®Google Scholar
• Pfizer Products Inc. Pyrrolopyrimidine derivatives useful in cancer treatment. WO2005116035; 2005
   Google Scholar
• Baker D, Tkalcevic G, Clark T, et al. Evaluation of antitumor, anti-angiogenic, and biomarker endpoints for orally active Tie-2 kinase inhibitors [abstract 2140]. AACR Annual Meeting, April 14-18, 2007, Los Angeles, CA
   Google Scholar
• Copeland RA, Pompliano DL, Meek TD. Drug–target residence time and its implications for lead optimization. Nat Rev Drug Discov 2006;5:730-9
   PubMed Web of Science ®Google Scholar
• Williams R. Discontinued drugs in 2007: oncology drugs. Expert Opin Investig Drugs 2008;17:1791-816
   PubMed Web of Science ®Google Scholar
• Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefore. WO2008080001; 2008
   Google Scholar
• Plexxikon Inc. Compounds modulating c-fms and/or c-kit and uses therefor. WO2008063888; 2008
   Google Scholar
• Pattarawarapan M, Burgess K. Molecular basis of neurotrophin-receptor interactions. J Med Chem 2003;46:5277-91
   Google Scholar
• Atwell S, Adams JM, Badger J, et al. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J Biol Chem 2004;279:55827-32
   PubMed Web of Science ®Google Scholar
• Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003;2:296-313
   PubMed Web of Science ®Google Scholar